WHEN YOUR PROVIDER SELECTS OVA1®, ASPIRA LABS® IS HERE TO HELP.

We work with your insurance company to determine the coverage allowed by your plan, and to assist you in claims reimbursement. Patients who meet specific financial criteria are eligible for the ASPIRA LABS® Financial Assistance Program. Do you have a question or concern about a bill for OVA1® testing? If so, please contact us at 888.403.6673.

FOR MORE INFORMATION
WWW.VERMILLION.COM
844.277.4721

OVA1® BETTER RISK DETECTION IN EARLY STAGE

Our goal is to provide simple and transparent billing policies to eliminate surprise costs. For many patients the out-of-pocket cost will be no more than $195.

For questions or to learn more, contact us at:
866.927.7472

OVARian CANCER RISK FOR WOMEN WITH A PELVIC MASS

OVA1® has the highest risk detection for all ages, ethnicities, stages and all types of ovarian cancer.

OVARian CANCER RISK FOR WOMEN WITH A PELVIC MASS

Being told you have a pelvic mass can be an overwhelming experience. Feel confident in what your facing with OVA1®
has a 96% rate of detection for risk of early stage ovarian cancer in a pelvic mass patient. The current testing, CA-125 has only a 69% rate of detection.

• Age
• Ethnicity
• Family history of ovarian cancer or other cancers
• Symptoms like bloating, pelvic pain, frequent urination, feeling full quickly or weight loss
• Suspicious features in a pelvic mass seen on ultrasound

OVA1® helps you and your provider decide with confidence what course of action is right for you.

Survival rates are greatly improved the earlier ovarian cancer is found. OVA1® outperforms the other tests at detecting risk for earlier stage ovarian cancer in patients with a pelvic mass. An elevated OVA1® score is not a diagnosis of cancer; it indicates increased risk.

OVA1® is a simple blood test cleared by the FDA that calculates a score based on five blood test results and menopausal status. Your score, along with your ultrasound results and other risk factors, can alert your provider if you have an increased risk of ovarian cancer.

OVA1® should not be used without an independent clinical evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery, incorrect use of the OVA1® test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Q: What doctor should I go to?
A: If you have an elevated cancer risk, you would benefit from a consult with a Gynecologic Oncologist.

Q: Will insurance cover OVA1®?
A: Yes, we accept and bill all insurances. Our billing experts work directly with your insurance to determine coverage. Most patients pay no more than $195.

Q: Has the FDA cleared OVA1®?
A: OVA1® has been cleared for women that are:
• Over 18 years
• Have a pelvic mass
• Have surgery planned
• Have not yet been referred to a Gynecologic Oncologist

Q: How can I benefit from OVA1®?
A: Some of the benefits of OVA1® include:
• Appropriate referral
• Timely medical management
• Improved survival and outcome when cancer risk detected at early stage.